|
Re: Liver Resection Pathology
Dear Marie,
Sounds like great news about the liver surgery, and certainly the ER+ nature of the tumour would help explain its persistence in the face of Herceptin. I have heard of this kind of difference before, and it lead to my having a bone biopsy; I've never had the liver mets biopsied as they were widespread, but we assume they are also ER+ and Her2+.
I am on Tamoxifen now, but was on Arimidex for 4 years after my first diagnosis. I have found both of theses relatively easy to tolerate - if the world's longest menopause can be thus described. (Hot flushes!) The AIs can also affect bone density, so you need to keep an eye on that.
Adding an AI sounds a reasonable way forward. I hope the side-effects are tolerable and that it keeps any further nasties away.
Best wishes.... Pam
__________________
Diagnosed 2004: Lumpectomy - 2 tumours, both grade 1 infiltrating duct carcinoma, about 12mm. ER+,
C-erbB-2 status 3+.
Clear margins, no nodal involvement.
Radiotherapy, i year Tamoxifen, 4 years Arimidex.
Rediagnosed 2012: Multiple bone metastases.
3/12: began on Marianne trial - T-DM1 + Pertuzamab/Placebo.
5/12:Unexpected development of numerous bilateral liver mets. Came off trial.
Started Docetaxol/ Herceptin + Zometa.
8/12:Bones stable +major regression in liver (!)
9/12:Can't take any more Docetaxol! Start on Herceptin and Tamoxifen. Cross fingers!
Changed to Denosumab.
11/12: Scan shows stable - yay!
11/13: Still stable :-) !!!
1/16: All stable, but lowered calcium, so switched to Zometa 3 monthly.
2/19: Happily still stable on Herceptin, Letrozole and 3 monthly Zometa.
|